Ophthalmology — Metastatic Tumors to the Eye and Adnexa

Basics

Description

Intraocular metastasis is the most common malignant tumor involving the eye.

The choroid is the most common site, accounting for approximately 63% of ocular metastases because of its exceptionally rich vascular supply.

Other sites include:

• Orbit/adnexa: ~32%
• Iris and ciliary body: ~6%
• Retina
• Vitreous
• Optic disc/optic nerve
• Eyelid

An important diagnostic point is that ~25% of patients have no known malignancy when the ocular metastasis is discovered. Even after systemic investigation, the primary site remains unknown in approximately 10%.

Most common primary:

• Women → breast carcinoma
• Men → lung carcinoma

Epidemiology

The incidence of ocular metastasis is increasing, probably because patients with systemic malignancies are surviving longer.

The true incidence is difficult to determine because:

• Many lesions are asymptomatic.
• Patients may have advanced systemic disease.
• Small ocular metastases may remain undetected.

Reported figures include:

• Postmortem incidence: ~10%
• Uveal metastasis in systemic cancer: 2.3–9.2%
• Orbital metastasis in systemic cancer: 2–4.7%

Risk Factors

The major risk factor for uveal metastasis is widespread metastatic disease.

Approximately 70–90% of patients already have metastases elsewhere when ocular metastasis is diagnosed.

A particularly important risk factor is metastatic involvement of ≥2 other organs.

Median interval between diagnosis of the primary malignancy and ocular metastasis is approximately 12–55 months, depending on tumor type.

Pathophysiology

Ocular metastases usually spread hematogenously.

The choroid has one of the highest blood flows of any tissue in the body and therefore has an extremely high metastatic efficiency.

This explains why the choroid is much more commonly affected than the retina or other intraocular structures.

Common Primary Cancers

Approximate distribution:

Primary tumor

Approximate frequency

Breast

40–47%

Lung

14–30%

Melanoma

~5%

GI malignancy

~4%

Kidney

2–4%

Prostate

1–4%

Diagnosis

History

Many patients are asymptomatic.

When symptoms occur, the most common is:

Blurred vision

Uveal metastasis

Other symptoms include:

• Scotoma
• Pain
• Redness
• Photophobia

Orbital metastasis

Typical symptoms include:

• Diplopia
• Proptosis
• Pain
• Ptosis
• Visible or palpable mass

Choroidal Metastasis

The choroid is the classic and most common site of ocular metastasis.

Clinical Features

• Bilateral in 20–50%
• Multifocal in approximately 30%
• Usually located in the posterior choroid
• Frequently involves the macular region
• Typically cream-yellow or cream-colored
• Often associated with substantial subretinal fluid

Color Can Suggest the Primary

Orange choroidal metastasis may occur with:

• Renal cell carcinoma
• Thyroid carcinoma
• Bronchial carcinoid

Gray-brown metastasis may suggest:

• Metastatic melanoma

A “leopard-skin” appearance can occur from clumps of brown pigment.

Iris Metastasis

Typical appearance:

• Yellow-white nodule
• Single or multiple lesions

Associated findings may include:

• Anterior uveitis / iridocyclitis
• Hyphema
• Secondary glaucoma

Therefore, an unexplained unilateral anterior uveitis with an iris mass—particularly in a patient with malignancy—should raise suspicion for metastasis.

Ciliary Body Metastasis

Usually appears as a:

• Solitary
• Sessile or dome-shaped mass

Associated manifestations include:

• Cataract
• Iridocyclitis
• Hyphema

Ultrasound biomicroscopy (UBM) is particularly useful for evaluating these lesions.

Retinal Metastasis

Retinal metastases are uncommon.

They can resemble:

• Occlusive retinal vasculitis
• Retinal infiltrative disease

Vitreous tumor seeding may accompany retinal involvement.

Vitreous Metastasis

Tumor cells can infiltrate the vitreous and produce an appearance resembling:

Primary vitreoretinal lymphoma.

Optic Nerve Metastasis

May result from:

1. Juxtapapillary extension of a choroidal metastasis, or
2. Direct isolated optic nerve metastasis

Typical findings include:

• Unilateral optic disc elevation
• Significant visual loss

Orbital Metastasis

Orbital metastasis may produce a mass effect causing:

• Proptosis
• Globe displacement
• Pain
• Chemosis
• Eyelid swelling

Soft-tissue infiltration can cause:

• Ptosis
• Restricted extraocular movements
• Diplopia

Important Pearl — Enophthalmos

Unlike most orbital tumors, scirrhous metastatic carcinoma can cause enophthalmos rather than proptosis.

Classically associated with:

• Breast carcinoma
• Gastric carcinoma

Carcinoid Metastasis

Orbital metastasis can occasionally be the first manifestation of a carcinoid tumor.

A useful pattern:

• Small-intestinal carcinoid → orbit
• Bronchial carcinoid → choroid

Pediatric Orbital Metastases

Metastatic orbital tumors are uncommon in children.

Important primary tumors include:

• Neuroblastoma
• Wilms tumor
• Ewing sarcoma
• Rhabdomyosarcoma

Eyelid Metastasis

Presentation is variable and may include:

• Solitary nodule
• Multiple nodules
• Diffuse eyelid infiltration

Diagnostic Testing

Initial Approach

Diagnosis is often primarily clinical, especially in a patient with a known systemic malignancy and characteristic choroidal lesions.

However, brain/CNS imaging is important because ocular metastases may coexist with intracranial metastases.

Fluorescein Angiography

Choroidal metastases typically demonstrate:

• Early hypofluorescence
• Late hyperfluorescence/leakage

Ultrasonography

A-scan

Usually demonstrates:

Moderate-to-high internal reflectivity

This can help distinguish metastasis from melanoma, which generally has lower internal reflectivity.

B-scan

Typically demonstrates:

• Acoustic solidity
• Choroidal mass
• Associated subretinal fluid

A mushroom configuration is unusual but can occasionally occur.

Orbital Imaging

MRI

Preferred when detailed evaluation of:

• Orbital soft tissue
• Optic nerve
• Intracranial structures

is required.

CT

Especially useful for:

• Bone involvement
• Osteoblastic or destructive lesions

For example, prostate metastases may have prominent osseous involvement.

Biopsy

Definitive diagnosis can be obtained with:

• Fine-needle aspiration biopsy (FNAB)
• Open biopsy

Biopsy is particularly useful when:

• There is no known primary cancer.
• The lesion is atypical.
• The diagnosis will change systemic management.

Immunohistochemistry can help identify the tissue of origin.

Important Systemic Implication

Detection of ocular metastasis generally indicates:

Stage IV systemic malignancy.

The patient therefore requires oncologic evaluation for:

• Restaging
• Identification of additional metastatic sites
• Selection of systemic treatment

Differential Diagnosis

Choroidal Metastasis

Important mimickers include:

• Choroidal melanoma
• Choroidal nevus
• Choroidal hemangioma
• Choroidal osteoma
• Choroidal lymphoma
• Inflammatory choroidal lesions

Iris Metastasis

Consider:

• Amelanotic iris melanoma
• Iris nevus
• Inflammatory granuloma

Orbital/Eyelid Metastasis

Differential includes numerous:

• Benign orbital tumors
• Primary malignant orbital tumors
• Lymphoproliferative lesions
• Inflammatory orbital disease

Treatment

Treatment depends heavily on:

• Primary malignancy
• Extent of systemic disease
• Number and location of ocular lesions
• Visual potential
• Symptoms
• Expected survival

The overall goals are usually vision preservation and symptom control while treating systemic disease.

Uveal Metastasis

External Beam Radiotherapy

A traditional and effective treatment.

Typical dose:

20–50 Gy

Reported tumor response:

63–83%

Visual improvement:

27–89%

Possible complications include:

• Ocular surface disease
• Cataract
• Radiation retinopathy

Systemic Therapy

Systemic treatment may cause regression of ocular metastases.

Options depend on tumor biology and include:

• Chemotherapy
• Hormonal therapy
• Targeted therapy
• Immunotherapy

Systemic therapy is particularly important when widespread metastatic disease is present.

Plaque Radiotherapy

Useful particularly for:

• Solitary choroidal metastasis
• Localized disease requiring concentrated radiation
• Recurrence after external beam radiotherapy

It delivers a high radiation dose directly to the lesion while reducing exposure to surrounding tissues.

Proton Beam Therapy

Advantages include:

• Highly precise radiation delivery
• Reduced radiation scatter
• Potentially shorter treatment course

Other Local Treatments

Selected lesions may be treated with:

• Photodynamic therapy
• Transpupillary thermotherapy
• Laser photocoagulation

These are generally reserved for carefully selected localized tumors.

Enucleation

Rarely required.

Main indication:

Blind, painful eye, particularly from severe secondary glaucoma or extensive tumor involvement.

Orbital Metastasis

Treatment depends strongly on systemic prognosis.

External beam radiotherapy

Often the principal local treatment.

Typical dose:

20–40 Gy over approximately 2–4 weeks

Potential benefits:

• Tumor shrinkage
• Reduced proptosis
• Relief of pain
• Improved motility
• Preservation of vision

Complications include:

• Cataract
• Radiation retinopathy

Brain metastases may require concurrent intracranial radiation.

Systemic Therapy for Orbital Disease

Chemotherapy may be useful for chemosensitive tumors, particularly:

Small-cell lung carcinoma

Hormonal therapy can be useful for:

• Breast carcinoma
• Prostate carcinoma

Orbital Surgery

Surgical debulking is usually palliative rather than curative.

It may be performed to improve:

• Pain
• Severe proptosis
• Diplopia

Orbital exenteration is rarely indicated but may be considered for a severely disfiguring orbital tumor.

Eyelid Metastasis

Treatment depends on lesion number, size, location, systemic disease and prognosis.

Options include:

• Excisional biopsy for small solitary lesions
• External beam radiotherapy for multiple/recurrent lesions
• Systemic anticancer therapy for disseminated disease
• Palliative therapy in terminal disease

Unknown Primary Tumor

In a small proportion of patients, the primary tumor remains unknown despite systemic investigation.

These patients generally have a poor prognosis.

A systemic therapeutic trial may sometimes be considered after appropriate oncologic evaluation.

Follow-Up

Management requires coordinated multidisciplinary care involving:

• Ophthalmology/ocular oncology
• Medical oncology
• Radiation oncology
• Other specialists depending on the primary malignancy

Ophthalmic follow-up should monitor:

• Response of existing lesions
• Development of additional metastases
• Fellow-eye involvement
• Subretinal fluid
• Visual function
• Treatment-related complications

Prognosis

Historically, ocular metastasis indicates advanced systemic disease.

Reported median survival after diagnosis has been approximately:

6–9 months

However, prognosis varies considerably according to the primary malignancy, molecular subtype, treatment response, and extent of systemic disease.

Relatively more favorable survival is seen with:

• Breast carcinoma
• Carcinoid tumors

Key Clinical Pearls

• Choroid is the most common site of ocular metastasis.
• Breast cancer is the most common primary in women; lung cancer in men.
• Approximately 25% may have no known cancer when the ocular lesion is discovered.
• Choroidal metastases are classically cream-colored, posterior, and associated with subretinal fluid.
• They can be bilateral and multifocal, an important clue against primary choroidal melanoma.
• Orange metastasis → think renal cell, thyroid, or carcinoid.
• Gray-brown metastasis → consider metastatic melanoma.
• Iris metastasis can produce uveitis + hyphema + secondary glaucoma.
• Scirrhous breast carcinoma can cause orbital enophthalmos, rather than the more usual proptosis.
• On ultrasound, metastases generally have moderate-to-high internal reflectivity, whereas melanoma classically has lower reflectivity.
• Ocular metastasis generally signifies advanced systemic metastatic disease, so systemic restaging is essential.

Ophthalmology – Marfan Syndrome

Basics

Description

Marfan syndrome is an autosomal dominant connective tissue disorder that primarily affects the:

• Cardiovascular system
• Musculoskeletal system
• Eyes

It is most commonly caused by pathogenic variants in FBN1, the gene encoding fibrillin-1.

A major ophthalmic hallmark is ectopia lentis, and Marfan syndrome is one of the most important causes of nontraumatic lens dislocation.

Epidemiology

Marfan syndrome affects approximately 4–6 per 10,000 individuals.

It affects males and females equally.

Approximately 25% of cases arise from a new mutation without a prior family history.

Risk Factors

Important risk factors include:

• Family history of Marfan syndrome
• Known pathogenic FBN1 mutation

Because inheritance is autosomal dominant, an affected individual has approximately a 50% chance of transmitting the disorder with each pregnancy.

Genetics

Marfan syndrome is most commonly associated with mutations in:

• FBN1 on chromosome 15q21

Fibrillin-1 is an important component of extracellular matrix microfibrils.

The disorder has:

• High penetrance
• Marked variability in clinical severity

Some phenotypically related connective-tissue disorders involve abnormalities in the TGF-β signaling pathway.

Pathophysiology

Fibrillin is essential for normal microfibril formation and extracellular matrix integrity.

Within the eye, fibrillin is found in structures including:

• Ciliary zonules
• Lens capsule
• Schlemm canal region
• Sclera
• Choroid
• Bruch membrane
• Lamina cribrosa
• Corneal tissues

Abnormal fibrillin helps explain the tendency toward:

• Ectopia lentis
• Axial myopia
• Retinal detachment
• Glaucoma
• Corneal abnormalities

Commonly Associated Conditions

Cardiovascular

Cardiovascular involvement is a major determinant of morbidity and mortality.

Important manifestations include:

• Aortic root dilatation
• Aortic aneurysm
• Aortic dissection
• Mitral valve prolapse
• Mitral regurgitation

Musculoskeletal

Typical features include:

• Tall stature
• Long extremities
• Arachnodactyly
• Scoliosis or kyphoscoliosis
• Pectus excavatum or pectus carinatum
• Joint laxity or hypermobility

Pulmonary

Possible manifestations include:

• Apical pulmonary blebs
• Spontaneous pneumothorax

Neurologic

A characteristic association is:

• Dural ectasia

Diagnosis

Diagnosis is based on the overall clinical picture, family history, cardiovascular findings, ocular findings, and genetic evaluation when appropriate.

Modern diagnosis uses the revised Ghent criteria rather than relying on a single physical feature.

History

Important history includes:

• Family history of Marfan syndrome
• Sudden cardiovascular death in relatives
• Known aortic disease
• Previous retinal detachment
• Progressive myopia
• Lens instability
• Musculoskeletal abnormalities
• Pneumothorax
• Back or neurologic symptoms that may suggest dural ectasia

Ophthalmic Examination

A complete eye examination should include:

• Visual acuity
• Refraction
• Slit-lamp examination
• Pupil dilation
• Lens position
• IOP
• Dilated peripheral retinal examination

Ectopia Lentis

Ectopia lentis is one of the most characteristic ocular findings.

It occurs in a substantial proportion of patients.

The classic displacement is superotemporal, although displacement can occur in other directions.

The zonules are structurally weak because fibrillin is a major component of the suspensory apparatus of the lens.

Visual Effects of Ectopia Lentis

Lens displacement can cause:

• High astigmatism
• Myopia
• Irregular refractive error
• Monocular diplopia
• Reduced best-corrected vision
• Amblyopia in children

Severe displacement can eventually require surgery.

Iris and Pupil

Patients may have:

• Poor pupillary dilation
• Iris or ciliary muscle hypoplasia

Poor dilation may make both examination and intraocular surgery more difficult.

Refractive Error

Axial myopia is common.

Patients may develop significant refractive error even in the absence of severe lens displacement.

Cataract

Cataract may occur earlier than expected for age.

Nuclear sclerosis may develop earlier than in the general population.

Vitreous Changes

Vitreous abnormalities may include:

• Early central vitreous liquefaction
• Posterior vitreous degeneration

These changes may contribute to retinal complications.

Retinal Detachment

Marfan syndrome is associated with a significantly increased risk of rhegmatogenous retinal detachment.

Risk is increased by:

• Axial myopia
• Abnormal vitreous
• Lens instability
• Prior lens surgery

Retinal detachment may occur at a younger age than in the general population.

Bilateral involvement is an important concern.

Diagnostic Tests

Genetic Testing

Molecular testing for FBN1 can support the diagnosis.

However, diagnosis remains clinical and multidisciplinary because genetic findings must be interpreted in the context of phenotype and family history.

Cardiovascular Imaging

Regular cardiovascular surveillance is essential.

Important studies include:

• Echocardiography
• CT angiography when needed
• MR angiography when needed

The key parameter is often the size and rate of growth of the aortic root.

Ophthalmic Imaging

If the fundus cannot be visualized adequately, especially with severe lens displacement or poor pupillary dilation, B-scan ultrasonography may help evaluate for retinal detachment.

Differential Diagnosis

The differential diagnosis of ectopia lentis includes:

• Trauma
• Homocystinuria
• Weill-Marchesani syndrome
• Familial isolated ectopia lentis
• Ectopia lentis et pupillae
• Aniridia
• Buphthalmos
• Sulfite oxidase deficiency
• Molybdenum cofactor deficiency
• Other metabolic or connective-tissue disorders

Marfan Syndrome vs Homocystinuria

This is an important clinical distinction.

Marfan Syndrome

Lens displacement is classically:

• Superotemporal

Patients often have:

• Tall habitus
• Aortic root disease
• Joint laxity

Homocystinuria

Lens displacement may occur in various directions and is classically described as inferonasal.

Patients may additionally have:

• Developmental or intellectual impairment
• Osteoporosis
• Thromboembolic disease

Treatment

Management is multidisciplinary.

The major goals are:

• Prevent aortic complications
• Optimize vision
• Treat lens instability
• Detect retinal detachment early
• Manage associated systemic disease

Cardiovascular Medical Therapy

Medical therapy is directed toward reducing stress on the aortic wall.

Common approaches include:

• Beta-blockers
• Angiotensin receptor blockers

The exact regimen should be determined by cardiology according to current Marfan and aortopathy guidelines.

Ophthalmic Management

Refractive Correction

Mild-to-moderate ectopia lentis may be managed with:

• Spectacles
• Contact lenses

Children must be monitored carefully for amblyopia.

Amblyopia

In children, asymmetric refractive error or lens displacement can cause amblyopia.

Treatment may include:

• Full optical correction
• Patching
• Other standard amblyopia therapy

Early intervention is important.

Lens Surgery

Lens removal may be considered when there is:

• Severe lens displacement
• Inadequate visual correction
• Cataract
• Secondary glaucoma
• Progressive visual disability
• Lens-related complications

Surgery can be technically challenging because of weak zonules.

Surgical Approach

Modern surgical technique depends on:

• Age
• Degree of lens displacement
• Capsular support
• Retinal status
• Surgeon experience

Pars plana or limbal approaches may be considered depending on the anatomy.

Because retinal detachment risk is increased, careful preoperative and postoperative retinal assessment is important.

Retinal Detachment Treatment

Retinal detachment should be managed promptly by a vitreoretinal surgeon.

Possible procedures include:

• Scleral buckle
• Pars plana vitrectomy
• Combined buckle and vitrectomy

The choice depends on:

• Lens position
• Break configuration
• Extent of detachment
• Vitreous anatomy

The fellow eye should also be examined carefully because bilateral retinal disease is more common than in the general population.

Referral

Patients commonly require coordinated care involving:

• Cardiology
• Ophthalmology
• Retina specialist
• Medical genetics
• Orthopedics
• Pulmonology
• Neurosurgery when dural ectasia is significant

Pregnancy Considerations

Pregnancy increases cardiovascular stress and can increase the risk of aortic enlargement and dissection in women with Marfan syndrome.

Risk is especially important when significant aortic root enlargement is already present.

Management should involve a multidisciplinary team including:

• Cardiology
• Maternal-fetal medicine
• Cardiothoracic surgery when indicated
• Genetics

Serial aortic imaging during pregnancy may be required.

Delivery planning depends largely on:

• Aortic diameter
• Rate of aortic enlargement
• Prior aortic surgery
• Overall cardiovascular status

Because recommendations are highly dependent on current aortopathy guidelines, fixed historical diameter thresholds should not be used without specialist assessment.

Fetal Considerations

Because Marfan syndrome is autosomal dominant:

• Each pregnancy has approximately a 50% chance of inheritance

Severity is highly variable.

A mildly affected parent can have a more severely affected child.

Genetic counseling is strongly recommended.

Follow-Up

Long-term monitoring should include:

• Regular echocardiography or other aortic imaging
• Periodic ophthalmic examinations
• Refraction
• Lens position assessment
• IOP
• Dilated retinal examination

Follow-up frequency depends on disease severity.

Lifestyle

Patients are generally advised to avoid activities that produce extreme cardiovascular stress.

This may include:

• Heavy isometric exercise
• Very heavy weightlifting
• High-intensity contact sports in selected patients

Exercise recommendations should be individualized by cardiology.

Patient Education

Patients should understand the symptoms of retinal detachment:

• New flashes
• Sudden increase in floaters
• Curtain or shadow across the vision
• Sudden peripheral visual field loss

These symptoms require urgent retinal evaluation.

Patients should also understand warning symptoms of aortic emergencies, such as sudden severe chest, back, or abdominal pain, and seek emergency care immediately.

Prognosis

Modern cardiovascular surveillance and treatment have greatly improved life expectancy.

Visual prognosis depends on:

• Severity of ectopia lentis
• Degree of myopia
• Presence of amblyopia
• Cataract
• Glaucoma
• Retinal detachment

Many patients maintain good useful vision with appropriate ophthalmic management.

Complications

Major ocular complications include:

• Ectopia lentis
• High myopia
• Amblyopia
• Cataract
• Glaucoma
• Retinal detachment
• Permanent visual loss

Major systemic complications include:

• Aortic aneurysm
• Aortic dissection
• Valvular disease
• Pneumothorax
• Dural ectasia

Key Clinical Pearls

• Marfan syndrome is an autosomal dominant fibrillin-1 connective-tissue disorder.
• Ectopia lentis is a major ophthalmic hallmark and is classically superotemporal.
• Marfan syndrome is an important cause of nontraumatic ectopia lentis.
• Patients commonly have axial myopia and increased retinal detachment risk.
• Always examine the peripheral retina carefully, particularly before and after lens surgery.
• The most life-threatening manifestation is aortic root disease, so ophthalmic findings can provide an important clue to a systemic diagnosis requiring cardiology evaluation.

Ophthalmology: Macular Hole

BASICS

Description

A macular hole is a partial-thickness or full-thickness defect involving the retina at the center of the macula, particularly the fovea. Because the fovea is responsible for high-resolution central vision, macular holes can cause significant central visual disturbance.

EPIDEMIOLOGY

Incidence

The estimated annual incidence of macular hole is approximately 7.8–8.7 cases per 100,000 persons.

The highest incidence occurs during the seventh decade of life.

Prevalence

Reported prevalence ranges from approximately 0.02% to 0.8%.

Macular holes occur more frequently in women than in men and most commonly affect individuals older than 55 years of age.

RISK FACTORS

A history of recent ocular trauma is an important risk factor, particularly in younger patients or when the macular hole develops following blunt injury.

PATHOPHYSIOLOGY

The development of a macular hole is strongly associated with abnormal vitreoretinal traction at the fovea.

Persistent attachment of the posterior vitreous cortex to the central macula can exert tractional forces on the foveal tissue. Progressive traction may initially distort the normal foveal contour and eventually produce a partial- or full-thickness retinal defect.

ETIOLOGY

Most macular holes develop idiopathically, particularly in older adults.

Traumatic macular holes can also occur, usually following blunt ocular injury.

DIAGNOSIS

History

Patients commonly report blurred or reduced central vision, distortion of straight lines or objects (metamorphopsia), or a central area of missing vision (central scotoma) in one eye.

Symptoms may develop acutely or subacutely. Because the fellow eye may maintain good visual function, some patients do not recognize the visual deficit until the unaffected eye is accidentally covered.

A history of recent ocular trauma should be specifically sought, particularly when the presentation is atypical or occurs in a younger patient.

Physical Examination

Visual acuity varies according to the size and stage of the macular hole and may range from approximately 20/25 to 20/400.

Patients with a well-established full-thickness macular hole often have visual acuity around 20/200, although considerable variation occurs.

The diagnosis is primarily established by careful biomicroscopic examination of the macula, usually with a handheld indirect lens or a fundus contact lens.

Typical examination findings include:

• A dark, round or oval defect located at the center of the fovea
• A small surrounding neurosensory retinal detachment, which may appear as a fluid-filled cuff
• Small yellow-white deposits or dots at the level of the retinal pigment epithelium
• A possible pseudo-operculum suspended above the macular hole

Gass Biomicroscopic Classification

Macular holes may be classified according to the traditional Gass staging system.

Stage 1: Impending Macular Hole

The foveal depression is lost and a central yellow abnormality develops.

Stage 1A is characterized by a central yellow spot.

Stage 1B is characterized by formation of a yellow ring.

At this stage, a complete full-thickness retinal defect has not yet formed.

Stage 2

A small full-thickness macular hole, traditionally measuring less than approximately 400 microns, becomes visible within the fovea.

Stage 3

A larger full-thickness macular hole, traditionally greater than approximately 400 microns, is present without a complete posterior vitreous detachment.

Stage 4

A full-thickness macular hole is present in association with a posterior vitreous detachment.

Watzke-Allen Test

The Watzke-Allen test may be used clinically to help distinguish a full-thickness macular hole from a lamellar hole, pseudohole, or other macular abnormality.

During the test, a narrow slit-lamp beam is projected across the center of the macular lesion using a macular contact lens.

A patient with a full-thickness macular hole may describe the light beam as having a central break, interruption, narrowing, or compression.

DIAGNOSTIC TESTS AND INTERPRETATION

Laboratory Testing

Routine laboratory investigations are not indicated in the evaluation of an uncomplicated macular hole.

Imaging

Optical Coherence Tomography

Optical coherence tomography (OCT) is the principal imaging technique used to confirm the diagnosis and characterize the macular hole.

OCT provides high-resolution cross-sectional images of the retina and can demonstrate:

• A partial- or full-thickness defect involving the fovea
• The size and configuration of the macular hole
• Vitreomacular adhesion or vitreomacular traction
• Intraretinal cystic changes around the hole
• Elevation of the retinal edges
• A pseudo-operculum when present
• The relationship between the posterior vitreous and the macula

OCT is also valuable for surgical planning and for documenting anatomical closure following treatment.

Diagnostic Procedures

Laser Aiming Beam Test

A small laser aiming beam, traditionally approximately 50 microns in diameter, may be directed toward the center of the suspected lesion.

A patient with a full-thickness macular hole may be unable to perceive the light spot when it is positioned directly over the hole. Patients with other macular abnormalities may still be able to see the aiming beam.

This test is used much less frequently now because OCT provides more detailed and objective anatomical information.

Pathological Findings

Histopathologic examination is generally unnecessary because tissue specimens are not routinely obtained during the diagnosis or surgical treatment of a macular hole.

DIFFERENTIAL DIAGNOSIS

Conditions that may resemble a macular hole include:

• Epiretinal membrane with a macular pseudohole
• Lamellar macular hole
• Vitreomacular traction
• Cystoid macular edema
• Macular cyst
• Pigment epithelial detachment
• Central serous chorioretinopathy

Careful fundus examination and OCT imaging are particularly useful for differentiating these conditions from a true full-thickness macular hole.

TREATMENT

Medication

There is no conventional medication that directly closes an established full-thickness macular hole.

Management is therefore primarily based on observation in selected cases or vitreoretinal intervention when treatment is indicated.

ADDITIONAL TREATMENT

Issues for Referral

Patients with a suspected or confirmed full-thickness macular hole should be referred to a vitreoretinal specialist for assessment and discussion of management options.

Complementary and Alternative Therapies

No complementary or alternative therapy has an established role in the treatment of macular holes.

SURGERY AND OTHER PROCEDURES

Surgical repair is the standard treatment for most visually significant full-thickness macular holes.

The usual procedure is pars plana vitrectomy with intraocular gas tamponade.

During surgery, the vitreous is removed and traction on the macula is released. In many cases, the surgeon also performs internal limiting membrane (ILM) peeling around the fovea to improve the likelihood of anatomical hole closure.

A gas bubble is then placed inside the eye to provide temporary internal tamponade and facilitate approximation of the edges of the macular hole.

Surgery is generally not considered an immediate emergency. However, once intervention has been recommended, repair is commonly undertaken within a relatively short period because longer-standing holes may have a less favorable visual prognosis.

Postoperative positioning instructions depend on the characteristics of the hole, the gas used, and the surgeon’s technique. Some patients may be instructed to maintain a face-down position for a period after surgery.

Patients with their natural crystalline lens remain at increased risk of developing or accelerating cataract formation after vitrectomy and may subsequently require cataract extraction.

INPATIENT CONSIDERATIONS

Initial Stabilization

Macular hole treatment is generally managed on an outpatient basis.

Hospital admission is not ordinarily required for uncomplicated cases.

ONGOING CARE

Follow-Up Recommendations

Patients should be evaluated by a vitreoretinal surgeon to determine whether surgical treatment is appropriate.

Following surgery, ophthalmic examinations are commonly performed at intervals such as:

• The first postoperative day
• Approximately 1 week after surgery
• Approximately 2–3 weeks after surgery
• Approximately 6–12 weeks after surgery

The exact follow-up schedule varies according to surgical findings, intraocular pressure, the type of gas tamponade used, retinal status, and postoperative recovery.

OCT may be repeated to confirm anatomical closure of the hole and monitor restoration of the foveal architecture.

PATIENT EDUCATION

Patients should be informed that a macular hole can also develop in the fellow eye. Reported rates of fellow-eye involvement are approximately 5–20%, depending on the vitreomacular anatomy and duration of follow-up.

Patients should therefore monitor the vision in each eye separately and promptly report new central blurring, distortion, or a central blind spot in the opposite eye.

Following vitreoretinal surgery, patients should also be educated about symptoms that may indicate a retinal tear or retinal detachment, including:

• New flashes of light
• A sudden increase in floaters
• A curtain, shadow, or veil across the visual field
• Sudden deterioration in peripheral or central vision

These symptoms require urgent ophthalmologic evaluation.

Patients who receive an intraocular gas bubble must follow the surgeon’s specific postoperative precautions, including restrictions related to altitude and certain forms of anesthesia until the gas has completely resolved.

PROGNOSIS

Modern macular hole surgery has a high anatomical success rate, with hole closure achieved in more than 90% of appropriately selected cases.

Visual recovery varies between patients. Successful anatomical closure usually improves or stabilizes central vision, although the final visual acuity depends on factors such as the size of the hole, duration of symptoms, preoperative retinal changes, and restoration of the outer retinal layers.

Earlier treatment of suitable macular holes is generally associated with a better potential for visual improvement than treatment of longstanding disease.

COMPLICATIONS

Potential complications associated with macular hole and its surgical treatment include:

• Cataract formation or progression, particularly after vitrectomy in phakic patients
• Retinal tears
• Retinal detachment
• Persistent or recurrent macular hole
• Intraocular pressure abnormalities following surgery
• Rare macular hole-associated retinal detachment

Although anatomical closure is achieved in most surgically treated cases, the degree of postoperative visual improvement remains variable.

Ophthalmology: Macular Corneal Dystrophy

BASICS

Description

Macular corneal dystrophy, also known as Groenouw corneal dystrophy type II or Fehr spotted dystrophy, is a bilateral, progressive, noninflammatory corneal disorder inherited in an autosomal recessive pattern. It is characterized by numerous stromal opacities accompanied by diffuse haziness of the intervening corneal tissue.

Corneal clouding generally becomes apparent during childhood, most commonly between 3 and 9 years of age.

The corneal lesions appear as poorly demarcated, gray-white opacities that extend toward the peripheral cornea. Deposits may involve the full thickness of the corneal stroma. As the disorder advances, abnormalities may extend to Descemet’s membrane and the corneal endothelium, resulting in guttae-like excrescences and corneal edema. Centrally, the lesions are usually situated more superficially, whereas peripheral deposits tend to occur deeper within the posterior stroma.

When compared with other stromal corneal dystrophies, particularly granular and lattice corneal dystrophies, macular corneal dystrophy is less common and tends to impair vision at an earlier age. Central corneal thickness may also be reduced early in the course of the disease. Unlike granular and lattice dystrophies, clear areas are generally absent between the opacities, and the deposits characteristically extend into the peripheral cornea. Patients often require corneal transplantation earlier in life. Although graft replacement is required less frequently than in some other corneal dystrophies, recurrence of macular dystrophy within the transplanted cornea remains possible.

Common clinical complaints include gradually worsening vision, glare, photophobia, and recurrent corneal epithelial erosions. Visual impairment often becomes severe during the second or third decade of life.

EPIDEMIOLOGY

Incidence and Prevalence

Macular corneal dystrophy is considered an uncommon disorder. Reliable population-based incidence and prevalence figures have not been well established in the medical literature.

RISK FACTORS

Parental consanguinity increases the likelihood of the condition because of its autosomal recessive inheritance pattern.

GENETICS

Macular corneal dystrophy follows an autosomal recessive mode of inheritance.

The associated genetic locus is located on chromosome 16q22. Mutations involve the carbohydrate sulfotransferase 6 gene (CHST6).

PATHOPHYSIOLOGY

The corneal opacities result from the abnormal accumulation of glycosaminoglycans (GAGs), also referred to as mucopolysaccharides. These materials are deposited both intracellularly and extracellularly within the corneal stroma and may also involve Descemet’s membrane and endothelial cells.

In macular corneal dystrophy, glycosaminoglycan material accumulates within the endoplasmic reticulum of affected cells. This differs from systemic mucopolysaccharidoses, in which similar substances accumulate predominantly within lysosomal vacuoles.

Histochemical staining demonstrates the deposits using Alcian blue, Hale colloidal iron, metachromatic stains, and periodic acid-Schiff (PAS).

Electron microscopy demonstrates abnormal GAG-containing material within keratocytes and endothelial cells. Similar fibrillogranular deposits can also be identified within the extracellular stromal matrix.

ETIOLOGY

Macular corneal dystrophy develops as a result of an inherited defect affecting glycosaminoglycan metabolism. The disorder is autosomal recessive and produces progressive, bilateral, noninflammatory accumulation of abnormal material throughout the corneal stroma.

These mucopolysaccharide deposits are responsible for the characteristic corneal clouding that usually becomes evident between 3 and 9 years of age.

DIAGNOSIS

History

A typical history consists of progressive bilateral corneal clouding beginning in childhood. Because the disorder is inherited in an autosomal recessive manner, patients may report a family history of the disease or parental consanguinity.

Symptoms generally include gradually declining visual acuity, glare, photophobia, and episodes of recurrent corneal erosion. Significant visual impairment commonly develops by the second or third decade of life.

Physical Examination

A complete ophthalmic evaluation should be performed. This includes assessment of visual function, measurement of intraocular pressure, slit-lamp examination, and a dilated fundus examination whenever the posterior segment can be adequately visualized.

If dense corneal opacification prevents visualization of the posterior segment, B-scan ultrasonography may be performed to exclude significant vitreoretinal or other posterior segment abnormalities.

Ultrasound pachymetry can be used to assess central corneal thickness, while specular microscopy, when technically possible, can provide information regarding corneal endothelial cell density and morphology.

Slit-Lamp Findings

Typical slit-lamp findings include:

• Multiple gray-white stromal opacities with poorly defined margins
• Extension of the lesions into the peripheral cornea
• Diffuse haze involving the corneal tissue between individual deposits
• Absence of clear intervening stromal spaces
• Deposits occurring at different depths throughout the corneal stroma
• More superficial involvement centrally and deeper involvement toward the corneal periphery
• Extension to Descemet’s membrane and the endothelium in advanced cases
• Guttae-like endothelial changes and corneal edema in severe disease

DIAGNOSTIC TESTS AND INTERPRETATION

Laboratory Testing

An enzyme-linked immunosorbent assay (ELISA) may be used to measure circulating sulfated keratan sulfate when further biochemical characterization is required.

Follow-Up Investigations

Clinical monitoring may include repeated:

• Slit-lamp examinations
• Corneal pachymetry
• Specular microscopy

These investigations help document progression of stromal disease, corneal thickness, and endothelial involvement.

Pathological Findings

Microscopically, macular corneal dystrophy is characterized by intracellular and extracellular deposition of glycosaminoglycans within the corneal stroma. Abnormal material may also be found in Descemet’s membrane and endothelial cells.

Unlike the lysosomal storage seen in systemic mucopolysaccharidoses, intracellular deposits in macular corneal dystrophy are predominantly located within the endoplasmic reticulum.

The abnormal deposits stain positively with Alcian blue, Hale colloidal iron, metachromatic dyes, and PAS.

Electron microscopy reveals abnormal material within keratocytes and endothelial cells as well as fibrillogranular deposits within the extracellular matrix.

Immunohistochemical testing using antibodies directed against sulfated epitopes of antigenic keratan sulfate (AgKS) allows macular corneal dystrophy to be divided into three biochemical subtypes. Despite these laboratory differences, their clinical appearances are generally similar.

Type I

In Type I macular corneal dystrophy, AgKS is not detectable in either the corneal tissue or serum.

Type IA

In Type IA, keratocytes demonstrate AgKS reactivity, whereas the extracellular stromal matrix and serum remain nonreactive.

Type II

In Type II, AgKS can be demonstrated both within the cornea and in the serum.

DIFFERENTIAL DIAGNOSIS

Conditions that may resemble macular corneal dystrophy include:

• Granular corneal dystrophy
• Lattice corneal dystrophy
• Avellino corneal dystrophy
• Schnyder crystalline corneal dystrophy

The diffuse stromal haze, lack of clear spaces between deposits, peripheral extension, and autosomal recessive inheritance are useful features for distinguishing macular corneal dystrophy from several other stromal dystrophies.

TREATMENT

Medication

Medical therapy is primarily directed toward relieving symptoms and managing recurrent epithelial erosions rather than eliminating the underlying stromal deposits.

Artificial tears may be used to lubricate the ocular surface and reduce symptoms associated with recurrent corneal erosions.

Topical hypertonic saline 5% may also be prescribed. Drops can be administered several times during the day, with hypertonic ointment applied at bedtime when appropriate. Hypertonic therapy can help reduce epithelial and stromal edema in symptomatic patients.

ADDITIONAL TREATMENT

General Measures

Tinted contact lenses may help reduce photophobia and glare.

A temporary pressure patch may occasionally be used to promote healing of a corneal epithelial defect, although careful observation is required because patching may increase the risk of infection.

Therapeutic or bandage contact lenses can be useful for recurrent corneal erosions. When used for an epithelial defect, topical antibiotic prophylaxis is commonly provided to reduce the risk of microbial keratitis.

Both pressure patching and therapeutic contact lens wear carry a potential risk of corneal infection. Patients therefore require close follow-up until complete re-epithelialization has occurred.

Indications for Referral

Prompt ophthalmologic reassessment is appropriate when there is:

• Progressive or substantial deterioration in vision
• A persistent or nonhealing corneal epithelial defect

SURGERY AND OTHER PROCEDURES

Phototherapeutic Keratectomy

Phototherapeutic keratectomy (PTK) can be considered in patients with relatively early disease when the deposits are primarily confined to the anterior corneal stroma.

PTK may also be useful in selected patients with troublesome recurrent corneal erosions.

Because the disorder can involve deeper layers over time, PTK is generally less suitable for advanced stromal disease.

Keratoplasty

Corneal transplantation may be necessary when deeper stromal opacification produces substantial visual impairment.

Possible procedures include lamellar keratoplasty, deep anterior lamellar keratoplasty (DALK), and penetrating keratoplasty (PKP).

Deep Anterior Lamellar Keratoplasty

DALK may be considered when the disease involves the corneal stroma but Descemet’s membrane and the endothelium remain unaffected.

Because the patient’s own endothelium is retained, DALK avoids endothelial graft rejection and reduces some of the risks associated with full-thickness transplantation.

Penetrating Keratoplasty

Penetrating keratoplasty provides full-thickness replacement of the diseased cornea and may be required when macular dystrophy extends deeply or involves Descemet’s membrane or the endothelium.

Even after successful keratoplasty, deposits may gradually recur within the donor cornea.

INPATIENT AND DISCHARGE CONSIDERATIONS

Patients being treated for recurrent epithelial erosions should remain under close observation until the epithelial surface has completely healed.

Because pressure patches and therapeutic contact lenses can increase the likelihood of corneal infection, patients should be instructed to seek urgent care if symptoms suggestive of infection develop.

ONGOING CARE

Follow-Up Recommendations

Long-term ophthalmic follow-up is required to monitor the progression of corneal opacities, visual function, and the development of complications.

The frequency of follow-up depends on disease severity and current symptoms.

Patients with stable disease may generally be reassessed every 6 to 12 months.

Patients experiencing recurrent epithelial erosions may require examination approximately every 1 to 7 days until healing is complete.

Patients managed with a pressure patch should usually be reassessed within approximately 24 to 48 hours.

PATIENT EDUCATION

Patients should understand that macular corneal dystrophy is a progressive inherited disorder and that visual function may worsen with time.

They should seek immediate ophthalmic attention if they develop significant ocular pain, sudden reduction in vision, marked redness, purulent discharge, or severe photophobia, as these symptoms may indicate an epithelial complication or corneal infection.

When corneal opacification causes substantial visual impairment, surgical treatment such as PTK or corneal transplantation may eventually be necessary.

Patients should also be informed that recurrence of abnormal corneal deposits is possible even after apparently successful surgery.

PROGNOSIS

Macular corneal dystrophy usually progresses gradually throughout life. Patients commonly experience increasing loss of vision together with glare, photophobia, and recurrent corneal erosions.

Visual impairment may become severe by the second or third decade, although the rate of progression can vary among individuals.

COMPLICATIONS

Important complications include progressive loss of visual acuity, glare, photophobia, recurrent corneal epithelial erosions, corneal edema, and possible endothelial dysfunction in advanced disease.

Although PTK and corneal transplantation can provide substantial symptomatic and visual improvement, recurrence of macular dystrophic deposits can occur following either procedure.

Ophthalmology – Lyme Disease

Basics

Description

Lyme disease is a multisystem infectious disease caused by Borrelia burgdorferi, a spirochete transmitted by infected Ixodes ticks.

It may involve the:

• Skin
• Nervous system
• Heart
• Joints
• Eyes

Ocular involvement can occur at several stages and may affect almost any ocular structure.

Epidemiology

Lyme disease is one of the most common tick-borne diseases in temperate regions of the Northern Hemisphere.

It is especially important in endemic regions of:

• Northeastern United States
• Mid-Atlantic United States
• Upper Midwest
• Europe
• Parts of Asia

Cases occur most often during spring, summer, and early fall, corresponding to periods of tick activity.

Risk Factors

Important risk factors include:

• Residence in an endemic area
• Travel to an endemic area
• Outdoor exposure in wooded or grassy areas
• Tick bite
• Exposure to deer, rodents, and tick-infested environments

General Prevention

The most effective preventive strategy is avoidance of tick bites.

Measures include:

• Avoiding dense brush and tall grasses when possible
• Wearing long sleeves and long pants
• Wearing light-colored clothing to make ticks easier to identify
• Using appropriate tick repellents such as DEET
• Performing a thorough skin and scalp examination after outdoor activity
• Showering after returning indoors
• Checking children carefully for ticks
• Checking outdoor pets
• Removing attached ticks promptly

Etiology

Lyme disease is caused by Borrelia burgdorferi, a motile spirochete.

Transmission occurs through the bite of infected Ixodes ticks.

Small mammals, especially rodents, act as important reservoirs.

Humans are incidental hosts.

Person-to-person transmission does not occur through ordinary contact.

Pathophysiology

After entering through the skin, the organism can disseminate through tissues and the bloodstream.

Borrelia can evade host immunity through changes in its surface proteins and interaction with complement regulatory pathways.

The clinical manifestations result from:

• Direct infection
• Tissue invasion
• Host inflammatory response
• Immune-mediated injury

Ocular manifestations may therefore reflect either active infection or secondary immune inflammation.

Diagnosis

History

Important questions include:

• Recent tick bite
• Travel to or residence in an endemic area
• Outdoor exposure
• Previous erythema migrans rash
• Fever or flu-like symptoms
• Joint pain
• Cardiac symptoms
• Neurologic symptoms

Ocular symptoms may include:

• Blurred vision
• Eye pain
• Redness
• Diplopia
• Floaters
• Photophobia
• Progressive visual loss

Clinical Stages

Early Localized Disease

The classic early manifestation is erythema migrans.

This is usually:

• Expanding
• Erythematous
• Often greater than several centimeters
• Sometimes associated with central clearing

It may produce the classic bull’s-eye appearance, although many lesions do not have this exact morphology.

The rash is often neither painful nor itchy.

Associated symptoms may include:

• Fever
• Chills
• Fatigue
• Headache
• Myalgia
• Arthralgia
• Lymphadenopathy

Early Ocular Findings

Possible findings include:

• Conjunctivitis
• Periorbital edema

Early Disseminated Disease

Dissemination can occur over weeks to months.

Systemic manifestations may involve:

• Nervous system
• Heart
• Joints
• Skin

Neurologic Manifestations

These may include:

• Meningitis
• Cranial neuropathy
• Radiculopathy
• Facial nerve palsy
• Headache
• Photophobia

Cardiac Manifestations

These may include:

• Palpitations
• Arrhythmia
• Atrioventricular block

Ocular Manifestations

Lyme disease can produce a broad range of ophthalmic findings.

External and Anterior Segment

Possible manifestations include:

• Conjunctivitis
• Episcleritis
• Scleritis
• Keratitis
• Exposure keratopathy secondary to facial nerve palsy
• Anterior uveitis
• Granulomatous uveitis

Cranial Nerve Palsies

Lyme disease can involve cranial nerves, including:

• CN III
• CN IV
• CN VI
• CN VII

Patients may present with:

• Diplopia
• Ptosis
• Extraocular motility abnormalities
• Facial weakness

Facial nerve palsy may lead to lagophthalmos and exposure keratopathy.

Intermediate and Posterior Segment Disease

Reported manifestations include:

• Pars planitis
• Vitritis
• Choroiditis
• Retinitis
• Macular edema
• Retinal vascular occlusion
• Retinal vasculitis

These findings are less common than neurologic or anterior segment manifestations.

Optic Nerve Manifestations

Possible findings include:

• Optic neuritis
• Retrobulbar optic neuritis
• Optic disc edema
• Ischemic optic neuropathy
• Optic atrophy

Patients may develop:

• Reduced visual acuity
• Dyschromatopsia
• Relative afferent pupillary defect
• Visual field defects

Late Disease

Late manifestations can persist or recur over months to years.

Systemic disease may include:

• Arthritis
• Chronic neurologic manifestations
• Acrodermatitis chronica atrophicans in some geographic regions

Late ocular findings may include:

• Stromal keratitis
• Episcleritis
• Orbital myositis
• Chronic uveitis
• Rare severe visual pathway involvement

Physical Examination

A complete examination should include:

• General physical examination
• Neurologic examination
• Full ophthalmic examination

Ophthalmic assessment should include:

• Visual acuity
• Pupillary examination
• Ocular motility
• Cranial nerve testing
• Slit-lamp examination
• IOP
• Dilated fundus examination

Diagnostic Testing

Serology

Laboratory diagnosis is based on two-tier serologic testing in the appropriate clinical setting.

Modern testing generally begins with an antibody screening immunoassay followed by a confirmatory second assay according to current testing algorithms.

Interpretation depends heavily on:

• Timing of symptoms
• Clinical presentation
• Pretest probability

Early infection can be seronegative before antibodies develop.

Cerebrospinal Fluid

Lumbar puncture may be indicated when there is concern for:

• Meningitis
• Neuroborreliosis
• Significant neurologic manifestations

CSF evaluation may include:

• Cell count
• Protein
• Intrathecal antibody assessment when appropriate

Additional Testing

Depending on the differential diagnosis, testing may include:

• Syphilis serology
• Other infectious testing
• Neuroimaging
• OCT
• Fluorescein angiography

These are guided by the specific ocular manifestation.

Differential Diagnosis

For optic nerve edema, retinitis, or neuro-ophthalmic disease, important alternatives include:

• Syphilis
• Cat-scratch disease
• Toxoplasmosis
• Acute retinal necrosis
• Multiple sclerosis
• Other infectious or inflammatory uveitides

Treatment

Treatment depends on the stage of disease and whether neurologic involvement is present.

Early Lyme Disease

Oral antibiotics are typically used.

Common agents include:

• Doxycycline
• Amoxicillin
• Cefuroxime axetil

Selection depends on:

• Age
• Pregnancy status
• Allergies
• Clinical manifestation

Neuro-Ophthalmic or Neurologic Lyme Disease

Patients with meningitis, significant cranial neuropathy, or other neuroborreliosis may require more intensive antibiotic therapy.

Depending on the presentation, treatment may include:

• Oral doxycycline
• Intravenous ceftriaxone

The exact regimen should follow current infectious-disease guidelines.

Ocular Inflammation

Inflammatory ocular manifestations may require treatment in addition to antibiotics.

Examples include:

• Topical corticosteroids for anterior uveitis
• Cycloplegic agents for pain and synechiae prevention
• Systemic anti-inflammatory therapy in selected severe disease

Antimicrobial treatment of the underlying Lyme infection should not be omitted when active infection is suspected.

Tick Removal

An attached tick should be removed promptly with fine-tipped forceps.

Recommended technique:

• Grasp the tick close to the skin
• Pull upward steadily
• Avoid twisting
• Avoid crushing or squeezing the body
• Clean the bite site afterward

Prompt removal reduces the likelihood of transmission.

Follow-Up

Follow-up depends on the severity of ocular disease.

Patients with active uveitis, optic nerve disease, or significant neuro-ophthalmic manifestations require close monitoring.

Follow-up should assess:

• Visual acuity
• Pupillary function
• Ocular motility
• Degree of inflammation
• IOP
• Optic nerve appearance
• Retinal findings

Patient Education

Patients should be advised to:

• Use protective clothing outdoors
• Use tick repellent appropriately
• Perform skin checks
• Remove ticks promptly
• Seek evaluation for expanding rash or new neurologic symptoms
• Report new visual symptoms promptly

Prognosis

Most appropriately diagnosed and treated patients have a favorable outcome.

Prognosis depends on:

• Speed of diagnosis
• Severity of neurologic involvement
• Type of ocular involvement
• Presence of optic nerve or retinal damage

Some inflammatory manifestations may persist despite eradication of infection.

Complications

Ophthalmic complications can include:

• Chronic uveitis
• Keratitis
• Scleritis
• Cranial nerve palsy
• Optic neuropathy
• Retinal vasculitis
• Macular edema
• Permanent visual loss

Key Clinical Pearls

• Lyme disease is caused by Borrelia burgdorferi and transmitted by Ixodes ticks.
• The classic early manifestation is erythema migrans, but not every patient recalls a rash or tick bite.
• Ocular involvement is diverse and may include conjunctivitis, uveitis, cranial nerve palsies, keratitis, optic neuritis, and retinitis.
• Facial nerve palsy can produce lagophthalmos and exposure keratopathy.
• Diagnosis relies on clinical context plus appropriate serologic testing.
• In neuro-ophthalmic disease, consider neuroborreliosis and coordinate treatment with infectious disease or neurology.
• Always consider alternative diagnoses such as syphilis, cat-scratch disease, toxoplasmosis, and acute retinal necrosis when posterior segment or optic nerve findings are present.

Ophthalmology – Lowe Syndrome

Basics

Description

Lowe syndrome, also called oculocerebrorenal syndrome of Lowe, is a rare multisystem disorder affecting primarily the eyes, nervous system, and kidneys.

The classic clinical pattern includes congenital ocular abnormalities, neurologic dysfunction, and proximal renal tubular disease.

Epidemiology

Lowe syndrome is very rare.

It almost exclusively affects males because it is usually inherited in an X-linked recessive pattern.

Genetics

Lowe syndrome is caused by pathogenic variants in the OCRL gene on chromosome Xq24–26.

The OCRL protein is an inositol polyphosphate 5-phosphatase involved in phosphoinositide metabolism and intracellular membrane trafficking.

Approximately one-third of affected males may have a de novo mutation, meaning there is no previous family history.

Rare affected females have been described, usually because of unusual X-chromosome abnormalities or highly skewed X-inactivation.

Inheritance

Because the disease is X-linked recessive, a female carrier has, with each pregnancy:

• A 25% chance of having an affected son
• A 25% chance of having an unaffected son
• A 25% chance of having a carrier daughter
• A 25% chance of having a noncarrier daughter

Genetic counseling is therefore important for affected families.

Pathophysiology

Loss of normal OCRL function causes abnormal phosphoinositide metabolism.

This disrupts several cellular processes, including:

• Membrane trafficking
• Endocytosis
• Cytoskeletal organization
• Maintenance of tight and adherens junctions
• Protein transport

These abnormalities contribute to the ocular, neurologic, and renal manifestations.

Ocular Pathophysiology

Cataract

Congenital cataracts are thought to result from abnormal development and migration of lens epithelial cells.

The cataracts are usually:

• Bilateral
• Dense
• Present at birth

They may involve the posterior lens and can severely impair visual development if untreated.

Glaucoma

Infantile glaucoma is associated with goniodysgenesis, meaning abnormal development of the anterior chamber angle.

This can cause elevated intraocular pressure early in life.

Commonly Associated Ocular Conditions

Important ocular manifestations include:

• Congenital cataract
• Infantile glaucoma
• Conjunctival or corneal keloid-like lesions
• Late retinal dystrophy
• Amblyopia
• Reduced vision

Neurologic Manifestations

Neurologic abnormalities commonly include:

• Generalized hypotonia
• Reduced or absent deep tendon reflexes
• Poor suck reflex in infancy
• Developmental delay
• Intellectual disability
• Behavioral disturbances
• Seizures

Hypotonia can be pronounced during infancy.

Renal Manifestations

The characteristic renal abnormality is proximal renal tubular dysfunction, often resembling Fanconi syndrome.

Findings may include:

• Proteinuria
• Proximal renal tubular acidosis
• Phosphate wasting
• Aminoaciduria
• Hypercalciuria
• Potassium disturbances
• Progressive renal impairment

Renal disease contributes substantially to systemic morbidity.

Skeletal Complications

Renal phosphate loss can result in:

• Renal rickets
• Osteomalacia
• Pathologic fractures
• Growth failure

Hypercalciuria can cause:

• Nephrocalcinosis
• Nephrolithiasis

Other Associated Conditions

Additional systemic findings can include:

• Cryptorchidism
• Failure to thrive
• Characteristic facial appearance
• Recurrent respiratory or gastrointestinal infections

Diagnosis

History

Important clues include:

• Family history of an X-linked disorder
• Congenital or early visual impairment
• Cataract noted in infancy
• Signs of infantile glaucoma
• Failure to thrive
• Developmental delay
• Hypotonia
• Seizures
• Renal abnormalities

Ocular Symptoms

Infants with glaucoma may develop:

• Photophobia
• Excessive tearing
• Corneal clouding
• Enlarged globe or buphthalmos

Congenital cataract may cause poor fixation or reduced visual responsiveness.

Physical Examination

General Examination

Children may demonstrate:

• Hypotonia
• Poor growth
• Developmental delay
• Characteristic facies
• Prominent or elongated forehead
• Fair complexion

Height, weight, and head circumference should be tracked carefully.

Ophthalmic Examination

A full examination should evaluate for:

• Congenital cataract
• Corneal clarity
• Corneal diameter
• Intraocular pressure
• Anterior chamber angle abnormalities
• Optic nerve damage
• Conjunctival or corneal keloids
• Retinal disease

Examination under anesthesia may be required in infants or uncooperative young children.

Carrier Females

Female carriers may show characteristic lens abnormalities despite being otherwise clinically unaffected.

These may include:

• Multiple fine punctate lens opacities
• Radially distributed or wedge-shaped lens changes
• Posterior lens opacities in some cases

Careful slit-lamp examination of the mother may therefore provide a useful diagnostic clue.

Diagnostic Tests

Laboratory Studies

Important investigations include:

• Renal function tests
• Serum electrolytes
• Urinalysis
• Urinary amino acids
• Assessment of acid-base status

These help characterize the degree of proximal tubular dysfunction.

Genetic Testing

Molecular testing for an OCRL mutation confirms the diagnosis in most cases.

Genetic testing also assists with:

• Carrier identification
• Family counseling
• Prenatal counseling

Neuroimaging

Brain MRI may show:

• Mild ventriculomegaly
• Periventricular cystic changes
• Other white-matter abnormalities

These findings may remain relatively stable over time.

Ophthalmic Imaging

If the fundus cannot be visualized because of dense cataract, B-scan ultrasonography may be helpful.

Optic nerve photography can assist with long-term glaucoma monitoring.

Pathological Findings

Lens abnormalities may include:

• Small discoid cataracts
• Posterior lenticonus
• Abnormal fetal nuclear development
• Capsular abnormalities

Anterior chamber pathology may demonstrate:

• Immature angle structures
• Anterior displacement of rudimentary ciliary processes

Retinal abnormalities can include:

• Peripheral cystoid degeneration
• Retinal folds
• Vascular hyalinization
• Mild gliosis

Differential Diagnosis

Important differential diagnoses include:

• Congenital rubella
• Peroxisomal disorders
• Mitochondrial disorders
• Other congenital cataract syndromes
• Other disorders combining developmental delay and renal disease

The combination of congenital cataract + infantile glaucoma + proximal renal tubular dysfunction strongly supports Lowe syndrome.

Treatment

Treatment is multidisciplinary and directed at the individual manifestations.

Cataract Management

Congenital cataracts often require early cataract surgery to prevent profound deprivation amblyopia.

After surgery, visual rehabilitation may require:

• Aphakic spectacles
• Contact lenses
• Intraocular lens implantation in selected patients
• Amblyopia therapy

Timing depends on age, cataract density, and overall clinical status.

Glaucoma Management

Infantile glaucoma may require:

• Medical IOP-lowering treatment initially
• Surgical treatment when angle abnormalities are significant

Common initial surgical procedures include:

• Goniotomy
• Trabeculotomy

Long-term monitoring is essential because glaucoma can cause irreversible optic nerve injury.

Amblyopia

Amblyopia should be treated aggressively when present.

Management may include:

• Optical correction
• Patching
• Penalization
• Early visual rehabilitation

Visual development should be monitored closely.

Low-Vision Rehabilitation

Children with residual visual impairment may benefit from:

• Low-vision assessment
• Educational accommodations
• Magnification devices
• Developmental visual support

Renal Treatment

Renal management may include:

• Sodium bicarbonate
• Sodium or potassium citrate
• Phosphate replacement
• Vitamin D supplementation

Treatment is individualized according to the child’s biochemical abnormalities.

The goal is to maintain appropriate:

• Calcium
• Phosphate
• Acid-base balance
• Parathyroid hormone levels

Renal Failure

Progressive renal insufficiency can eventually require:

• Dialysis
• Renal transplantation

Management should be coordinated with pediatric nephrology.

Neurologic Treatment

Treatment may include:

• Antiseizure medications
• Developmental therapy
• Physical therapy
• Occupational therapy
• Speech therapy

Behavioral problems may require psychological or psychiatric management.

Referral

Patients typically require coordinated care involving:

• Pediatric ophthalmology
• Glaucoma specialist
• Medical genetics
• Nephrology
• Neurology
• Developmental pediatrics
• Physical therapy
• Occupational therapy
• Speech therapy
• Psychology or psychiatry

Surgical referral may also be needed for cryptorchidism.

Follow-Up

Regular ophthalmic follow-up is required for:

• Cataract management
• Glaucoma surveillance
• Optic nerve monitoring
• Amblyopia treatment
• Retinal dystrophy
• Visual development

Systemic monitoring should include:

• Renal function
• Growth
• Electrolytes
• Bone health
• Development
• Seizure control

Diet

Dietary recommendations are primarily determined by the degree of renal tubular dysfunction.

Patients may require individualized management of:

• Phosphate
• Sodium
• Potassium
• Calcium
• Fluid intake

A pediatric nephrologist or dietitian should guide these adjustments.

Patient Education

Families should understand that Lowe syndrome is a chronic multisystem genetic disorder requiring lifelong coordinated care.

Genetic counseling is particularly important for:

• Mothers
• Sisters
• Other potentially affected female relatives

Families should also be educated about:

• Seizures
• Renal complications
• Glaucoma symptoms
• Visual rehabilitation
• Developmental services

Prognosis

Prognosis varies according to the severity of renal, neurologic, and respiratory involvement.

Historically, life expectancy has been reduced, with major causes of mortality including:

• Progressive renal disease
• Respiratory complications
• Seizures
• Severe infections

Some patients survive well into adulthood with modern multidisciplinary care.

Visual Prognosis

Visual outcome depends primarily on:

• Timing of cataract treatment
• Severity and control of glaucoma
• Development of amblyopia
• Presence of retinal dystrophy

Early cataract and glaucoma treatment can produce meaningful visual benefit.

Later retinal dystrophy can limit long-term visual potential.

Complications

Major complications include:

• Congenital cataract
• Amblyopia
• Infantile glaucoma
• Optic nerve damage
• Retinal dystrophy
• Developmental delay
• Seizures
• Renal insufficiency
• Rickets and fractures
• Nephrocalcinosis
• Respiratory complications

Key clinical pearl: Lowe syndrome should be suspected in a male infant with bilateral congenital cataracts, infantile glaucoma, severe hypotonia/developmental delay, and proximal renal tubular dysfunction. Examination of the mother for characteristic punctate lens opacities can provide an additional clue to the X-linked carrier state.

Ophthalmology – Leukemia / Blood Dyscrasias

Basics

Description

Ocular involvement in leukemia and other blood dyscrasias can occur through several different mechanisms:

• Direct infiltration by malignant leukemic cells
• Secondary hematologic abnormalities, especially anemia and thrombocytopenia
• Hyperviscosity and vascular occlusion
• Opportunistic infection caused by immunosuppression
• Complications of chemotherapy, radiotherapy, or other treatment

Intraocular leukemia refers to direct accumulation of leukemic cells within ocular tissues.

Potential sites include:

• Choroid — most common site of direct infiltration
• Retina
• Optic nerve
• Iris
• Ciliary body
• Vitreous
• Anterior chamber

However, leukemic retinopathy caused by hematologic abnormalities is considerably more common than true leukemic infiltration.

Epidemiology

Ocular abnormalities are relatively common in patients with leukemia, particularly in acute leukemia.

Important points:

• Ocular findings are more common in acute than chronic leukemia.
• Many patients with ocular findings are asymptomatic.
• Adults appear to develop ocular manifestations more frequently than children.
• Retinal hemorrhages are among the most frequent findings.
• Only a minority of ocular lesions represent direct malignant infiltration.

Because ocular disease may be clinically silent, ophthalmic examination can reveal abnormalities even in patients without visual complaints.

Age Considerations

Children

Acute lymphoblastic leukemia (ALL) is the predominant childhood leukemia.

Ocular involvement can result from:

• Leukemic infiltration
• Anemia
• Thrombocytopenia
• Hyperleukocytosis
• Opportunistic infection
• Treatment-related complications

Adults

Acute myeloid leukemia (AML) is the predominant acute leukemia in adults.

Chronic leukemias occur more commonly in older adults and may initially follow a relatively indolent course.

Risk Factors for Leukemia

Important associations and risk factors include:

• Previous chemotherapy
• Previous radiation exposure
• Myelodysplastic syndromes
• Certain genetic disorders, including Down syndrome
• Benzene exposure
• Cigarette smoking
• Family history of leukemia

Pathophysiology of Ocular Disease

There are four major mechanisms.

1. Direct Leukemic Infiltration

Malignant leukocytes directly infiltrate ocular structures.

The choroid is the most commonly infiltrated ocular tissue histopathologically because of its rich vascular supply.

Other sites include:

• Retina
• Optic nerve
• Iris
• Ciliary body
• Vitreous
• Anterior chamber

2. Leukemic Retinopathy

Leukemic retinopathy usually does not represent direct invasion of the retina by malignant cells.

Instead, it commonly results from:

• Anemia
• Thrombocytopenia
• Abnormal coagulation
• Hyperviscosity
• Vascular endothelial injury

This produces retinal hemorrhage and ischemic changes.

3. Hyperviscosity Syndrome

Hyperviscosity results from abnormally increased blood viscosity.

It can occur with:

• Marked leukocytosis in leukemia
• Polycythemia vera
• Waldenström macroglobulinemia
• Multiple myeloma and other monoclonal gammopathies

The resulting sluggish retinal circulation produces a venous stasis retinopathy.

4. Opportunistic Infection

Both leukemia itself and its treatment can produce profound immunosuppression.

Important ocular infections include:

• CMV retinitis
• Herpetic retinal necrosis
• Ocular toxoplasmosis
• Candida and other fungal infections

Distinguishing infection from direct leukemic infiltration can sometimes be difficult but is crucial because treatment is very different.

Diagnosis

History

Patients may be:

• Completely asymptomatic
• Known to have leukemia
• Presenting with ocular manifestations before systemic leukemia has been recognized

Ocular symptoms can include:

• Blurred or decreased vision
• Floaters
• Visual field abnormalities
• Photopsias

Systemic clues include:

• Fever
• Persistent fatigue
• Weight loss
• Recurrent infections
• Easy bruising or bleeding
• Pallor
• Dyspnea
• Lymphadenopathy

These manifestations reflect the major hematologic consequences of leukemia:

• Anemia → pallor, fatigue, dyspnea
• Thrombocytopenia → bleeding
• Abnormal leukocytes → infection and immune dysfunction

Ocular Manifestations

Leukemic Retinopathy

This is considerably more common than direct retinal leukemic infiltration.

Retinal Hemorrhages

Retinal hemorrhage is the most common ocular finding.

Hemorrhages are often:

• Bilateral
• Multifocal

They may occur at different retinal levels:

• Preretinal
• Intraretinal
• Subretinal

Severe hemorrhage can break through into the vitreous.

Roth Spots

Large retinal hemorrhages may contain white centers, producing the classic appearance of Roth spots.

The white centers can represent:

• Fibrin-platelet aggregates
• Ischemic material
• In some cases, leukemic cellular infiltration

Roth spots are not specific for leukemia and occur in several systemic diseases.

Cotton-Wool Spots

Cotton-wool spots may occur because of retinal microvascular ischemia.

They represent focal disruption of axoplasmic flow within the retinal nerve fiber layer.

Direct Retinal Leukemic Infiltration

A characteristic infiltrative lesion can appear as a:

• Fuzzy
• Flat
• White retinal lesion

It may be associated with:

• Retinal hemorrhage
• Overlying vitreous cells

Lesions can be:

• Unifocal or multifocal
• Unilateral or bilateral

Choroidal Infiltration

The choroid is the most common site of direct ocular leukemic infiltration.

Choroidal involvement may be:

• Localized
• Diffuse

It can produce:

• Choroidal thickening
• Retinal pigment epithelial abnormalities
• Serous retinal detachment
• Visual loss

Optic Nerve Infiltration

Leukemia may infiltrate the optic nerve.

Possible findings include:

• Optic disc swelling
• Disc infiltration
• Reduced visual acuity
• Color vision impairment
• Relative afferent pupillary defect when asymmetric
• Visual field defects

Optic nerve infiltration is particularly important because it may represent central nervous system leukemic involvement and requires urgent systemic evaluation.

Anterior Segment Infiltration

Direct leukemic involvement can affect the:

• Iris
• Ciliary body
• Anterior chamber

Possible manifestations include:

• Iris thickening or nodules
• Anterior chamber cells
• Secondary glaucoma
• Hyphema
• Pseudohypopyon

Pseudohypopyon

A leukemic pseudohypopyon represents accumulation of malignant cells in the anterior chamber rather than ordinary inflammatory leukocytes.

It should raise suspicion for direct leukemic infiltration, particularly in a patient with known leukemia.

Vitreous Involvement

Direct infiltration may produce:

• Vitreous cells
• Vitreous haze

However, vitreous inflammation in an immunocompromised patient also raises concern for opportunistic infection.

Hyperviscosity Retinopathy

Typical findings include:

• Dilated and tortuous retinal veins
• Multiple retinal hemorrhages
• Microaneurysms
• Retinal edema
• Intraretinal or subretinal fluid
• Peripheral retinal nonperfusion
• Neovascularization in severe disease

The appearance can resemble a mild central retinal vein occlusion, particularly when bilateral.

Bilateral venous stasis-type retinopathy should prompt consideration of a systemic hyperviscosity disorder.

Chronic Myeloid Leukemia

Patients with chronic myeloid leukemia can develop:

• Peripheral retinal capillary nonperfusion
• Microaneurysms
• Retinal hemorrhage
• Retinal neovascularization

Severe hyperleukocytosis can markedly disturb retinal microcirculation.

Opportunistic Ocular Infections

CMV Retinitis

CMV is an important infectious retinitis in severely immunocompromised patients.

Other Important Infections

Consider:

• Toxoplasmosis
• Candida
• Cryptococcus
• Nocardia
• Herpes-family viral retinitis

Infection can closely mimic malignant infiltration.

Diagnostic Tests

Hematologic Evaluation

When leukemia is suspected, evaluation should be performed together with hematology/oncology.

Investigations can include:

• Complete blood count with differential
• Peripheral blood smear
• Bone marrow aspiration and/or biopsy
• Appropriate systemic staging

Depending on the clinical circumstances, additional testing may include:

• Lumbar puncture with CSF analysis
• Coagulation studies
• Serum protein electrophoresis
• Other tests for hyperviscosity disorders

Ocular Imaging

Depending on the findings, useful studies can include:

• Fundus photography
• Optical coherence tomography (OCT)
• Fluorescein angiography
• B-scan ultrasonography

Fluorescein angiography can help demonstrate:

• Capillary nonperfusion
• Microaneurysms
• Neovascularization
• Vascular leakage

Neuroimaging

If optic nerve infiltration is suspected, obtain appropriate neuroimaging, generally:

• MRI of the orbits
• MRI of the brain

Evaluation for CNS leukemia may also be necessary.

Diagnostic Vitrectomy or Biopsy

When the diagnosis remains uncertain, particularly when distinguishing malignant infiltration from opportunistic infection, diagnostic procedures may include:

• Aqueous sampling
• Vitreous sampling
• Diagnostic pars plana vitrectomy
• Biopsy in selected lesions

Samples can undergo:

• Cytology
• Flow cytometry
• Microbiologic testing
• Molecular testing as appropriate

Differential Diagnosis

Important differentials include:

Infectious

• CMV retinitis
• Candida
• Toxoplasmosis
• Nocardia
• Cryptococcus
• Syphilis
• Other opportunistic infections

Noninfectious

• Primary vitreoretinal lymphoma
• Sarcoidosis
• Intermediate uveitis
• Other causes of retinal hemorrhage
• Central retinal vein occlusion
• Other hyperviscosity syndromes

Treatment

Systemic Leukemia Treatment

The primary treatment is directed at the underlying hematologic malignancy.

Management should be performed by a hematologist/oncologist and may include:

• Systemic chemotherapy
• Targeted therapy
• Immunotherapy
• Hematopoietic stem-cell transplantation

The exact treatment depends on the type and molecular characteristics of the leukemia.

Most secondary ocular manifestations improve when the underlying leukemia and hematologic abnormalities are controlled.

Treatment of Direct Ocular Infiltration

Direct leukemic infiltrates frequently respond to systemic treatment.

If ocular infiltration persists despite adequate systemic therapy, additional treatment may be considered, including:

• Local ocular radiotherapy in selected cases
• Other local or CNS-directed therapy according to the site of involvement and leukemia subtype

Treatment of Leukemic Retinopathy

Treatment is primarily correction of the underlying systemic abnormalities.

This may involve:

• Treatment of leukemia
• Correction of severe anemia
• Management of thrombocytopenia
• Blood product support when clinically indicated

Hemorrhagic retinopathy can improve substantially once the hematologic abnormalities resolve.

Hyperviscosity Syndrome

The underlying hematologic disorder must be treated urgently when hyperviscosity is clinically significant.

Depending on the cause, emergency therapy can include:

• Leukapheresis for selected cases of severe symptomatic hyperleukocytosis
• Plasma exchange for certain paraproteinemias such as Waldenström macroglobulinemia

Definitive systemic therapy is still required.

Retinal Neovascularization

When significant peripheral nonperfusion produces retinal neovascularization, panretinal photocoagulation may be indicated in selected cases.

Opportunistic Infection

Ocular infection requires organism-specific antimicrobial treatment.

This is particularly important because increasing immunosuppression for presumed leukemic infiltration could worsen an unrecognized infection.

Follow-Up

Patients with leukemia require coordinated management between:

• Hematology/oncology
• Ophthalmology

Ophthalmic monitoring should assess:

• Visual acuity
• Anterior segment
• IOP
• Vitreous
• Retina and macula
• Optic nerve

More frequent follow-up is warranted with:

• Direct leukemic infiltration
• Significant retinal hemorrhage
• Hyperviscosity retinopathy
• Optic nerve involvement
• Opportunistic infection

Prognosis

Visual prognosis depends on the mechanism of ocular involvement.

Hemorrhagic leukemic retinopathy may improve substantially when anemia and thrombocytopenia are corrected and the leukemia is controlled.

Direct leukemic infiltration generally indicates more significant systemic disease and has historically been associated with a poorer prognosis.

Ocular findings can therefore provide important information about both visual and systemic disease severity.

Key Clinical Pearls

• Retinal hemorrhage is the most common ocular manifestation of leukemia.
• Most leukemic retinopathy is caused by anemia and thrombocytopenia rather than direct malignant infiltration.
• The choroid is the most common site of direct leukemic ocular infiltration histopathologically.
• White-centered retinal hemorrhages (Roth spots) are suggestive but not specific for leukemia.
• Bilateral venous stasis retinopathy should raise suspicion for hyperviscosity.
• Optic nerve infiltration is an ophthalmic and oncologic concern because it may indicate CNS involvement.
• In an immunocompromised leukemia patient with a new retinal or vitreous lesion, always distinguish leukemic infiltration from opportunistic infection.

Click here to start customizing

Ophthalmology – Leber Hereditary Optic Neuropathy

Basics

Description

Leber hereditary optic neuropathy (LHON) is a mitochondrial optic neuropathy that causes acute or subacute, painless central visual loss, usually beginning in one eye and then affecting the fellow eye within weeks to months.

The disease is caused by maternally inherited mitochondrial DNA mutations that impair oxidative phosphorylation.

Typical features include:

• Painless central visual loss
• Central or cecocentral scotoma
• Dyschromatopsia
• Sequential involvement of the fellow eye
• Predominance in young adult males

Visual acuity often deteriorates to 20/200 or worse.

Epidemiology

LHON is uncommon.

Reported incidence in European populations is approximately 1 in 30,000 to 1 in 50,000.

The disease most commonly becomes symptomatic between 18 and 35 years of age, although onset can occur in childhood or later adulthood.

Men are affected much more frequently than women.

Risk Factors

The most important risk factor is inheritance of a pathogenic mitochondrial DNA mutation from the mother.

Environmental factors may influence whether a carrier develops visual loss.

Important modifiable risk factors include:

• Smoking
• Heavy alcohol consumption
• Exposure to mitochondrial toxins
• Certain medications with mitochondrial toxicity
• Nutritional deficiency in susceptible individuals

Smoking appears to be particularly important in genetically susceptible carriers.

Genetics

LHON is inherited through mitochondrial DNA, so transmission is maternal.

Affected men do not transmit the mutation to their children.

Affected or carrier women may transmit the mutation to all of their children.

The three major pathogenic mutations are:

• m.3460G>A
• m.11778G>A
• m.14484T>C

Together, these account for the great majority of LHON cases.

The m.11778G>A mutation is the most common.

Penetrance

Not every individual carrying an LHON mutation develops optic neuropathy.

Penetrance is incomplete and strongly influenced by sex.

Men have a substantially greater lifetime risk of visual loss than women.

This means that a family can contain:

• Asymptomatic carriers
• Severely affected individuals
• Individuals with onset at different ages

despite carrying the same mitochondrial mutation.

Heteroplasmy

Some patients have heteroplasmy, meaning both normal and mutant mitochondrial DNA coexist in the same individual.

Others are homoplasmic, meaning essentially all mitochondrial DNA carries the mutation.

The proportion of mutant mitochondrial DNA may influence disease risk, although blood heteroplasmy does not necessarily reflect the exact mitochondrial composition within the optic nerve.

Pathophysiology

The major LHON mutations affect subunits of mitochondrial complex I, also called NADH dehydrogenase.

This impairs oxidative phosphorylation and reduces efficient cellular energy production.

Retinal ganglion cells, particularly those forming the papillomacular bundle, have high metabolic demands and appear especially susceptible.

The result is:

• Retinal ganglion cell dysfunction
• Axonal degeneration
• Optic nerve atrophy
• Permanent central visual loss in many patients

Oxidative stress and free-radical injury also appear to contribute.

General Prevention

In known carriers or affected families, patients should be advised to avoid:

• Smoking
• Heavy alcohol use
• Recreational toxins
• Unnecessary exposure to mitochondrial-toxic medications

A healthy balanced diet is reasonable.

These measures do not guarantee prevention but may reduce environmental stress on vulnerable mitochondria.

Commonly Associated Conditions

Most patients have isolated optic neuropathy.

Rare systemic manifestations can occur, including:

• Cardiac conduction abnormalities
• Wolff-Parkinson-White syndrome
• Other pre-excitation syndromes
• Prolonged QT interval
• Palpitations
• Syncope

Rare neurologic manifestations include:

• Tremor
• Ataxia
• Dystonia
• Hyperreflexia
• Peripheral neuropathy
• Hearing impairment
• Movement disorders
• Nystagmus

A multiple sclerosis-like syndrome associated with LHON is sometimes referred to as LHON-plus.

Diagnosis

History

The classic presentation is:

• Painless visual decline
• Initially involving one eye
• Followed by the fellow eye weeks or months later

Approximately half of patients develop fellow-eye involvement within a few months.

Patients may describe:

• Central blur
• Loss of fine detail
• Difficulty recognizing faces
• Reduced color perception
• Central blind spot

Peripheral vision is often relatively preserved.

Visual Acuity

Visual acuity may initially be mildly reduced but often declines substantially.

Many affected eyes reach:

• 20/200
• Counting fingers
• Occasionally worse

The degree of visual loss varies.

Color Vision

Color vision impairment can occur before major loss of central acuity.

Patients may have:

• Red-green dyschromatopsia
• Generalized color desaturation
• Difficulty with formal color plate testing

Color testing is useful in monitoring optic nerve dysfunction.

Visual Fields

The characteristic defect is a:

• Central scotoma
• Cecocentral scotoma

The defect often enlarges as the disease progresses.

Peripheral visual fields are usually better preserved than central vision.

Fundus Findings

During the acute phase, classic findings may include:

• Circumpapillary telangiectatic microangiopathy
• Peripapillary retinal nerve fiber layer swelling
• Vascular tortuosity
• Hyperemia of the optic disc

Importantly, there is typically little or no leakage from the optic disc on fluorescein angiography, despite the appearance of swelling.

This helps distinguish LHON from true inflammatory optic disc edema.

Pseudoedema

The peripapillary nerve fiber layer may appear swollen, but this is not typical inflammatory disc edema.

Fluorescein angiography generally shows absence of significant disc leakage.

Over time, swelling resolves and is replaced by:

• Temporal pallor
• Diffuse optic atrophy
• Thinning of the retinal nerve fiber layer

Diagnostic Tests

Genetic Testing

Mitochondrial DNA testing is the most important confirmatory test.

Testing should initially include the three major mutations:

• m.3460G>A
• m.11778G>A
• m.14484T>C

Broader mitochondrial sequencing may be considered when clinical suspicion is high but these common mutations are absent.

Optical Coherence Tomography

OCT is useful for documenting structural changes.

Early disease may show:

• Thickening of the retinal nerve fiber layer
• Peripapillary swelling

Later disease shows:

• RNFL thinning
• Ganglion cell complex loss
• Optic atrophy

Ganglion cell loss may become detectable early in the disease course.

Fluorescein Angiography

Fluorescein angiography may demonstrate:

• Peripapillary telangiectatic vessels
• Microangiopathy

A characteristic feature is the absence of significant leakage from the disc.

Visual Evoked Potentials

VEPs may show:

• Reduced amplitude
• Delayed latency
• Absent responses in severe disease

They are supportive but not diagnostic.

Color Testing

More detailed testing may include:

• Farnsworth D-15
• Farnsworth-Munsell 100 Hue test

These can detect optic nerve dysfunction before severe central vision loss.

Cardiac Evaluation

An ECG may be considered because some LHON patients have associated cardiac conduction abnormalities.

This is particularly appropriate if the patient reports:

• Palpitations
• Syncope
• Exercise intolerance

Neuroimaging

MRI of the brain and orbits may be obtained, particularly in atypical cases or when excluding other optic neuropathies.

MRI is often normal or nonspecific.

Imaging is important when the presentation is unusual because LHON can mimic:

• Optic neuritis
• Compressive optic neuropathy
• Demyelinating disease

Differential Diagnosis

Important differential diagnoses include:

• Dominant optic atrophy
• Nutritional optic neuropathy
• Toxic optic neuropathy
• Tobacco-alcohol optic neuropathy
• Multiple sclerosis-associated optic neuritis
• Compressive optic neuropathy
• Wolfram syndrome
• Other inherited mitochondrial optic neuropathies

Dominant Optic Atrophy

Dominant optic atrophy usually presents:

• Earlier in life
• More gradually
• Bilaterally and symmetrically

LHON more typically causes relatively rapid sequential central visual loss.

Optic Neuritis

Typical demyelinating optic neuritis often causes:

• Eye pain with movement
• More acute unilateral loss
• Younger adult presentation
• MRI abnormalities in many cases

LHON is characteristically painless and frequently becomes bilateral sequentially.

Toxic and Nutritional Optic Neuropathy

These may also produce:

• Bilateral central scotomas
• Dyschromatopsia
• Temporal optic pallor

A careful history of:

• Alcohol
• Tobacco
• Medications
• Nutritional status

is essential.

Treatment

Idebenone

Modern management may include idebenone, a synthetic short-chain benzoquinone related to coenzyme Q10.

It is intended to improve mitochondrial electron transport and reduce oxidative stress.

Benefit appears greatest when treatment is started relatively early in the disease course.

Availability and approval vary by country, and management should be coordinated with a neuro-ophthalmologist or mitochondrial disease specialist.

Supportive Metabolic Therapy

Historically, various supplements have been used, including:

• Coenzyme Q10
• Riboflavin
• Thiamine
• Vitamin B12
• Folic acid
• L-carnitine
• Alpha-lipoic acid
• Antioxidants

Evidence for many of these therapies is limited compared with idebenone.

They should not replace specialist-directed treatment.

Gene Therapy

Gene therapy has been studied extensively for LHON, particularly for the m.11778G>A mutation.

Several trials have investigated intravitreal delivery of mitochondrial-targeted genetic constructs.

This remains a rapidly evolving area and availability depends on region and regulatory approval.

Surgery

There is no useful surgical treatment for the underlying mitochondrial optic neuropathy.

Procedures such as optic nerve sheath decompression do not improve LHON.

Referral

Patients with suspected LHON should be referred to a:

• Neuro-ophthalmologist
• Medical geneticist or genetic counselor
• Mitochondrial disease specialist when appropriate

Cardiology referral may be indicated if conduction abnormalities are suspected.

Low-Vision Rehabilitation

Because central vision may be severely affected while peripheral vision remains relatively intact, low-vision services are extremely important.

Useful interventions may include:

• Magnifiers
• Electronic reading devices
• Screen magnification
• Text-to-speech software
• High-contrast aids
• Orientation and mobility training

Visual rehabilitation can substantially improve independence.

Genetic Counseling

Genetic counseling is essential.

Important inheritance principles include:

• Transmission is maternal.
• An affected father does not transmit LHON mtDNA to his children.
• A carrier mother can transmit the mutation to both sons and daughters.
• Not every carrier develops visual loss.
• Men are more likely to become affected than women.

Female relatives are especially important to identify because they can transmit the mutation to future generations.

Follow-Up

Patients should be monitored with:

• Visual acuity
• Color vision
• Visual fields
• OCT
• Fundus examination

During the acute phase, relatively frequent follow-up may help document progression from one eye to the other and monitor structural changes.

Patient Education

Patients should be advised to:

• Stop smoking
• Avoid heavy alcohol consumption
• Maintain good nutrition
• Avoid unnecessary mitochondrial-toxic exposures
• Inform physicians of the mitochondrial diagnosis before starting new medications
• Seek genetic counseling
• Use low-vision rehabilitation early if needed

Family members may benefit from genetic testing after appropriate counseling.

Prognosis

The prognosis varies considerably according to the mitochondrial mutation.

m.11778G>A

This mutation generally has the poorest spontaneous visual recovery.

m.14484T>C

This mutation has a significantly better chance of partial spontaneous recovery.

m.3460G>A

The prognosis is generally intermediate.

Better recovery has also been associated with:

• Younger age at onset
• Larger optic disc size in some studies
• Earlier treatment
• Certain mitochondrial genetic backgrounds

Visual Recovery

When recovery occurs, patients may notice:

• Small islands of clearer vision within the central scotoma
• Gradual improvement in central acuity
• Better color perception

Recovery can occur months or even years after onset.

However, many patients are left with significant permanent central visual impairment.

Complications

The principal complication is permanent bilateral central visual loss.

Secondary consequences may include:

• Loss of driving ability
• Difficulty reading
• Occupational limitations
• Reduced independence
• Psychosocial distress

Rare systemic complications include cardiac conduction abnormalities and neurologic manifestations.

The key clinical pearl is: LHON should be suspected in a young adult—especially a man—with painless, severe central visual loss in one eye followed weeks to months later by similar involvement of the fellow eye, particularly when maternal male relatives have experienced comparable visual loss.